B8562

BD 1047 dihydrobromide

≥95% (HPLC)

• 동의어(들): BD 1047 dihydrobromide
• 실험식(Hill 표기법): C₁₃H₂₀Cl₂N₂ · 2 HBr
• CAS Number: 138356-21-5
• Molecular Weight: 437.04
• MDL number: MFCD00792739
• UNSPSC 코드: 12352200
• PubChem Substance ID: 329773309
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥95% (HPLC)
• 양식: powder
• 저장 조건: desiccated
• 색상: white
• solubility: H₂O: >5 mg/mL
• 저장 온도: 2-8°C
• SMILES string: Br.Br.CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1
• InChI: 1S/C13H20Cl2N2.2BrH/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11;;/h4-5,10H,6-9H2,1-3H3;2*1H
• InChI key: WOALTFHGLDVJHK-UHFFFAOYSA-N

설명

애플리케이션

BD 1047 dihydrobromide has been used as an antagonist of sigma-1 receptor in hepatocellular carcinoma cells.

BD 1047, a selective, putative σ1 receptor antagonist, is used in sigma receptor research to help differentiate and characterized the function and role of the sigma1 receptor versus other sigma receptor subtypes. BD 1047 is used to help define the role of σ1 receptors in neurological processes.

생화학적/생리학적 작용

BD-1047 is a selective, putative σ receptor antagonist with antidystonic activity.

BD-1047 is a selective, putative σ receptor antagonist with antidystonic activity. BD-1047 has >50-fold selectivity at σ1 over σ2 and also >100-fold selectivity over opiate, phencyclidine, muscarinic, dopamine, α1- & α2-adrenoceptor, 5-HT1, and 5-HT2. Though s receptor antagonism is consistent with antipsychotic, especially anti-schizophrenic, activity, BD-1047 shows only modest activity in animal screens for antipsychotics.

In human immunodeficiency (HIV)-1 seropositive patients, BD 1047 along with other antioxidants may aid in reduction of cathepsin B- based neuropathology.

안전성 정보

• 픽토그램: GHS05,GHS07
• 신호어: Danger
• 유해 및 위험 성명서: H315,H318,H335
• 예방조치 성명서: P280 - P302 + P352 - P305 + P351 + P338 + P310
• Hazard Classifications: Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
• 표적 기관: Respiratory system
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable